case_images: PMC11177723_01
case_images: Longitudinal trends in kidney function and proteinuria before and after initiation of delayed-release budesonide. The blue and red lines represent the estimated glomerular filtration rate (eGFR, calculated by the 2021 CKD-EPI equation) and the urine protein/creatinine ratio, respectively. The graph displays the changes from 2015 to 2023. The green line marks the start of delayed-release (DR) budesonide treatment, and the orange line indicates the initiation of SGLT-2 Inhibitor therapy.
case_images: 10.1177_23247096241260964-fig1.jpg
case_images: PMC11177723_01_10.1177_23247096241260964-fig1.jpg
case_images: fig1-23247096241260964
case_images: His proteinuria also increased gradually despite treatment, reaching its highest level of 1100 mg/g by October 2022, up from 551 mg/g in 2015 (Figure 1). After 12 months of therapy with DR budesonide, his eGFR remained stable, and his proteinuria decreased from 1339 mg/g in December 2022 to 452 mg/g in November 2023 (Figure 1).